Hodgkin Lymphoma-Like Posttransplant Lymphoproliferative Disorder (HL-Like PTLD) Simulates Monomorphic B-Cell PTLD Both Clinically and Pathologically

2006 ◽  
Vol 30 (4) ◽  
pp. 470-476 ◽  
Author(s):  
Sean D. Pitman ◽  
Qin Huang ◽  
Craig W. Zuppan ◽  
Edward H. Rowsell ◽  
Jeffrey D. Cao ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Lymphoproliferative Disorder ◽  
Posttransplant Lymphoproliferative Disorder

scholarly journals Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder

2018 ◽  
Vol 102 (11) ◽  
pp. 1914-1923 ◽  
Author(s):  
Heiner Zimmermann ◽  
Nina Babel ◽  
Daan Dierickx ◽  
Franck Morschhauser ◽  
Peter Mollee ◽  
...  
Keyword(s):  
B Cell ◽  
Clinical Features ◽  
Lymphoproliferative Disorder ◽  
Posttransplant Lymphoproliferative Disorder ◽  
Relapse Risk

Hodgkin Lymphoma–like Posttransplantation Lymphoproliferative Disorder

2006 ◽  
Vol 130 (4) ◽  
pp. 558-560 ◽  
Author(s):  
Barbara Semakula; ◽  
Jon V. Rittenbach ◽  
Jun Wang
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Lymphoproliferative Disorder ◽  
Molecular Genetic ◽  
Lymphoproliferative Disorders ◽  
World Health ◽  
Solid Organ ◽  
World Health Organization Classification ◽  
Health Organization ◽  
Posttransplantation Lymphoproliferative Disorder

Abstract Posttransplantation lymphoproliferative disorders (PTLD) are a heterogeneous group of monoclonal or polyclonal lymphoproliferative lesions that occur in immunosuppressed recipients following solid organ or bone marrow transplantation, including 4 categories: (1) early lesions (reactive plasmacytic hyperplasia, and infectious-mononucleosis–like PTLD), (2) polymorphic PTLD, (3) monomorphic PTLD (including B-cell neoplasms and T-cell neoplasms), and (4) Hodgkin lymphoma (HL) and HL-like PTLD in the current World Health Organization classification. Although HL-like PTLD has been grouped with classic HL PTLD, controversy remains as to whether it is truly a form of HL or whether it should be more appropriately considered as a form of B-cell PTLD. The current available literature data indicate the presence of important immunophenotypic, molecular genetic, and clinical differences between HL PTLD and HL-like PTLD, suggesting that HL-like PTLD is in fact most often a form of B-cell PTLD. Distinction from true HL may be important for clinical management and prognosis.

Sign in / Sign up

Export Citation Format

Share Document